SCYNEXIS to Present at the BIO Digital International Convention 2021
SCYNEXIS, Inc. (NASDAQ: SCYX) announced its participation in the BIO Digital International Convention from June 10-11 and June 14-18, 2021. Dr. Marco Taglietti, the company's CEO, will present the FDA-approved BREXAFEMME® (ibrexafungerp tablets) and discuss late-stage clinical trials for recurrent vaginal yeast infections and life-threatening fungal infections like Candida auris. Attendees can view the presentation ahead of one-on-one meetings starting June 14. SCYNEXIS focuses on developing innovative antifungal treatments aimed at tackling drug-resistant infections.
- None.
- None.
- Company presentation will highlight BREXAFEMME® (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital setting
JERSEY CITY, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present at the BIO Digital International Convention to be held virtually from June 10 – 11 and 14 – 18, 2021. The Company presentation will highlight BREXAFEMME® (ibrexafungerp tablets), in addition to other late-stage clinical trials evaluating ibrexafungerp in the community setting for recurrent vaginal yeast infections, and as a treatment for life threatening fungal infections, including Candida auris, in the hospital setting. The presentation is now available to registered attendees.
Attendees at BIO Digital will be able to view the SCYNEXIS Company Presentation before live meetings in the BIO One-on-One Partnering™ system begin on June 14. To meet with the Company at BIO Digital, you can find registration information here.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. We are developing our lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. The New Drug Application (NDA) for BREXAFEMME® (ibrexafungerp tablets) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. For more information, visit www.brexafemme.com. We are also continuing late-stage clinical development of ibrexafungerp for the prevention of recurrent VVC as well as the treatment of life-threatening invasive fungal infections in hospitalized patients. For more information, visit www.scynexis.com.
About BIO
BIO is the world's largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Subscribe to Good Day BIO.
CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com
Media Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com
FAQ
What will SCYNEXIS present at the BIO Digital International Convention 2021?
When is the BIO Digital International Convention taking place?
What is the significance of BREXAFEMME® for SCYNEXIS?
What types of infections is SCYNEXIS focusing on with ibrexafungerp?
How can attendees access the SCYNEXIS presentation at BIO Digital?
